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ORIGINAL ARTICLE

Plasma derived from human umbilical cord blood: Potential
cell‐additive or cell‐substitute therapeutic for
neurodegenerative diseases
Jared Ehrhart1 | Paul R. Sanberg2,3,4,5 | Svitlana Garbuzova-Davis2,3,4,6
1
Saneron CCEL Therapeutics, Inc., Tampa,
Florida

Abstract

2

Limited efficacy of current therapeutic approaches for neurodegenerative disease

Center of Excellence for Aging and Brain
Repair, Morsani College of Medicine,
University of South Florida, Tampa, Florida

has led to increased interest in alternative therapies. Cord blood plasma (CBP)
derived from human umbilical cord blood (hUCB) may be a potential therapeutic.
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Benefits of CBP injection into rodent models of aging or ischaemic stroke have been
demonstrated, though how benefits are elicited is still unclear. The present study
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evaluated various factors within the same samples of CBP and human adult blood
plasma/sera (ABP/S). Also, autologous CBP effects vs. ABP/S or foetal bovine serum
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supplements on mononuclear cells from hUCB (MNC hUCB) in vitro were determined. Results showed significantly low concentrations of pro‐inflammatory cytoki-
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Tampa, Florida

nes (IL‐2, IL‐6, IFN‐γ, and TNF‐α) and elevated chemokine IL‐8 in CBP. Significantly
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hUCB viability and decreased apoptotic cell activity. We are first to demonstrate

higher levels of VEGF, G‐CSF, EGF and FGF‐basic growth factors were determined
in CBP vs. ABP/S. Autologous CBP media supplements significantly increased MNC
the unique CBP composition of cytokines and growth factors within the same CBP
samples derived from hUCB. Also, our novel finding that autologous CBP promoted
MNC hUCB viability and reduced apoptotic cell death in vitro supports CBP's potential as a sole therapeutic or cell‐additive agent in developing therapies for various
neurodegenerative diseases.
KEYWORDS
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1 | INTRODUCTION

cells4 in vitro. Moreover, the therapeutic potential of CBP administration into rats modelling acute ischaemic stroke was demonstrated

Cord blood plasma (CBP) is commonly obtained from human umbili-

by enhancement of neurogenesis and reduction of inflammation

cal cord blood (hUCB) during cell isolation and has mainly been con-

leading to significant post‐stroke functional recovery.5 Also, tissue

sidered a waste product. However, the trophic effect of CBP has

inhibitor of metalloproteinases 2, a plasticity‐enhancing protein from

been shown in replacing standard serum during the expansion of

CBP, has been found to promote restoration of hippocampal func-

1

2

tion and memory in aged 18 months old mice after CBP treatment.6

hUCB‐derived T‐lymphocytes, or human endothelial colony‐forming

A recent study7 showed beneficial functional improvement in an

hUCB‐derived mesenchymal stem cells, human dental stem cells,
3
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Alzheimer's disease (AD) mouse model by injection of a specific frac-

commercially available source (Sigma‐Aldrich, St. Louis, MO, USA).

tion from cord blood serum compared to adult blood serum. Addi-

Upon receipt of ABP/S, samples were aliquoted and stored at

tionally, umbilical cord serum has being effectively employed for the

−20°C.

8,9

treatment of corneal defects

10

and neurotrophic keratitis

in

humans.
In a relatively recent study,11 we showed the ability of CBP to
modulate mitogen‐induced in vitro proliferation of mononuclear cells

2.2 | Human umbilical cord blood processing and
plasma isolation

(MNC) isolated from the peripheral blood of amyotrophic lateral scle-

Human umbilical cord blood (hUCB) units (n = 20), with maternal

rosis (ALS) patients. Interestingly, three distinct cell responses to the

blood samples negative for all tested infectious markers, were pro-

mitogenic factor phytohemmagglutinin were noted, suggesting

cessed to obtain an autologous CBP fraction and mononuclear cell

altered lymphocyte functionality in ALS patients. MNC responses

population (MNC hUCB, U‐CORD‐CELL™, Saneron CCEL Therapeu-

were shown to be regulated by CBP treatment in vitro. Additionally,

tics, Inc., Tampa, FL, USA) as detailed below. Upon receipt, the cord

the apoptotic activity of MNCs isolated from ALS patients was sig-

blood units were diluted (1:1) with sterile phosphate buffered saline

nificantly reduced by supplementing media with CBP. Thus, these

(PBS) without Mg2+ or Ca2+ (Sigma‐Aldrich, St. Louis, MO, USA). The

study results have not only broadened the therapeutic application of

cord blood was then fractionated using the density gradient solution

CBP for ALS, but also further expanded its potential for treatment

Ficoll (Ficoll‐Paque Premium: 1.078 g/mL, Cat. No. 17544202; Milli-

of other neurodegenerative disorders with immunological aspects.

poreSigma, St. Louis, MO, USA) in the Sepax 2 fully automated cell

It has been shown that CBP contains high amounts of various

processing system (Biosafe America Inc., Houston, TX, USA). This

growth factors, such as vascular endothelial growth factor (VEGF),

allowed for the sterile collection of both CBP and MNC hUCB from

insulin‐like growth factor‐1 and transforming growth factor (TGF)‐β,

each unit of cord blood. The CBP was further centrifuged at 3000 g

3,12

that are required for cell maintenance during hematopoiesis.

for 10 minutes to remove any additional red blood cells. The CBP

Although CBP can exert a favourable effect on hematopoietic stem

was then aliquoted and stored at −20°C. The MNC hUCB cell num-

cells, whether CBP elicits therapeutic benefit as an additive to, or

bers and viability were determined using the Vi‐CELL Viability Ana-

substitute for, cells must be determined before developing clinically

lyzer (Beckman Coulter, Brea, CA, USA). MNC hUCB was then

relevant

frozen at 5 × 107 cells per vial using a proprietary cryopreservation

CBP‐based

therapies

for

various

neurodegenerative

diseases.
The aim of this study was to characterize the composition of fac-

media (Saneron CCEL Therapeutics, Inc.) and stored in liquid
nitrogen.

tors in CBP derived from hUCB, which might mediate therapeutic
benefit. First, cytokine and growth factor profiles were analyzed in
the same CBP samples. Second, the efficacy of autologous CBP on
MNC hUCB viability in vitro was investigated. Finally, the effect of

2.3 | Cytokine profile in human umbilical cord
blood plasma

autologous CBP upon the apoptotic MNC hUCB response in vitro

A human ultrasensitive cytokine 10‐plex panel (Invitrogen, Carlsbad,

was examined. These study results provide a basis for further estab-

CA, USA; Cat. No. LHC6004) was used as previously described13 to

lishment of CBP as a potential self‐contained therapeutic or as a

determine the concentrations of cytokines within CBP (n = 20) and

supportive diluent for MNC hUCB infusion in treatment of neurode-

ABP/S (n = 6) in triplicate, following the manufacturer's protocol. All

generative diseases.

measurements were performed by an investigator blinded to the
sample source. Granulocyte‐macrophage colony‐stimulating factor

2 | MATERIALS AND METHODS
2.1 | Ethics statement

(GM‐CSF) and cytokine levels of interleukin (IL)‐1β, IL‐2, IL‐4, IL‐5,
IL‐6, IL‐8, IL‐10, interferon‐gamma (IFN‐γ), tumour necrosis factor‐
alpha (TNF‐α) and GM‐CSF were quantified using the Bio‐Rad Bio‐
Plex® Luminex 200 multiplex assay system (Bio‐Rad Laboratories

The human umbilical cord blood (hUCB) units were collected by

Inc., Hercules, CA, USA). The Bio‐Rad Bio‐Plex® 200 software

Texas Cord Blood Bank (TCBB, GenCure, West San Antonio, TX,

(BioRad Laboratories Inc., Hercules CA, USA) was used to calculate

USA) and provided to Saneron CCEL Therapeutics, Inc. for research

the sample cytokine concentrations according to a standard curve

purposes. The cord blood units were obtained from full‐term preg-

and results were presented as picograms of analyte per milliliter

nancies by vaginal delivery. The umbilical cord blood units were

(pg/mL).

received within 48 hours of collection. Maternal blood samples, collected as the same time as the cord blood, were tested by TCBB for
infectious disease markers of HIV, hepatitis B and C, syphilis, CMV
and HTLV I&II, and test results were provided for validation of the

2.4 | Growth factor profile in human umbilical cord
blood plasma

cord blood units. Each cord blood unit in the study was negative for

A human growth factor 4‐plex panel (Invitrogen; Cat No. LHC0007)

all infectious disease markers as determined in maternal blood.

was employed to determine various growth factor levels within CBP

Human adult blood plasma or sera (ABP/S) was obtained from a

(n = 20) and ABP/S (n = 6) samples in triplicate, following the
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manufacturer's protocol. All measurements were performed by an

were incubated at 37°C with 5% CO2 for 5 days. Media was chan-

investigator blinded to the source of the samples. Levels of VEGF,

ged at 24 hours and 3 days after cell plating. On day 5, the apop-

granulocyte colony‐stimulating factor (G‐CSF), epidermal growth fac-

totic activity of the cells was determined using the HT TiterTACS™

tor (EGF) and fibroblast growth factor basic (FGF‐basic) were deter-

Assay kit (Trevigen, Bio‐Techne, Minneapolis, MN, USA; Cat No.

mined using the Bio‐Rad Bio‐Plex® Luminex 200 multiplex assay

4822‐96‐K) accordingly to the manufacturer's instructions. Briefly,

(BioRad Laboratories Inc., Hercules CA, USA). The Bio‐Rad Bio‐Plex®

the cells were washed with 200 μL of sterile PBS, then quickly fixed

200 software (BioRad Laboratories Inc., Hercules CA, USA) was used

using a 3.7% PBS buffered formaldehyde solution. The cells were

to calculate the sample growth factor concentrations accordingly to

washed once more with PBS and then permeabilized with Cytonin™

a standard curve and results were presented as pg/mL.

(50 μL/well). TACS‐Nuclease™ (50 μL/well) was then added to designated wells to determine total absorbance. The plate was incubated

2.5 | Viability of MNC hUCB cultured with
autologous CBP

for 60 minutes at 37°C following a wash with PBS. The endogenous
peroxidase activity was quenched with a 3% hydrogen peroxide
solution. The wells were then washed once more with PBS and a 1x

Cryopreserved MNC hUCB cells (n = 4 units) were quickly thawed

TdT labelling buffer reaction mix was added to the wells and incu-

at 37°C, washed with PBS, and centrifuged at 400 g for 5 minutes.

bated at 37°C for 60 minutes. To stop the labelling reaction, 1x TdT

Cell quantity and viability were determined using a haemocytometer.

stop buffer was added to the well and incubated for 5 minutes, fol-

The cells were then re‐suspended with phenol‐free RPMI‐1640

lowed by a wash with PBS. The streptavidin‐HRP enzyme solution

media (Gibco, Dublin, Ireland; Cat. No. 11835030) and plated in a

was then added to the wells and incubated for 10 minutes at RT.

24‐well cell culture plate at a density of 5 × 104 cells/well. Pre‐desig-

After an additional wash with PBS, the TACS‐Sapphire substrate

nated wells were supplemented with 10% of autologous CBP, ABP/

solution was added and incubated for 30 minutes at RT with light

S, or foetal bovine serum (FBS) (Gibco, Dublin, Ireland; Cat No.

protection. Stop solution of 0.2N HCl was added to each well and

10438026) upon initial plating in duplicate. Cells were incubated at

absorbance at 450 nm was measured using a spectrophotometer

37°C with 5% CO2 for 5 days. Media was changed at 24 hours and

(SpectraMax Plus 384 microplate reader, Molecular Devices, LLC.,

3 days after cell plating. On day 5, cell viability was determined

San Jose, CA, USA). Results were calculated as the percentage of rel-

using the LIVE/DEAD viability/cytotoxicity kit (Molecular Probes, Cat

ative apoptotic absorbance values to maximum absorbance values

No. R37601) accordingly to the manufacturer's instructions. Briefly,

determined for each culture condition. Cell morphology was

the culture media was replaced with 250 μL of fresh PBS in each

observed using phase contrast images (n = 6/supplement) obtained

well. In an equal volume to PBS, LIVE/DEAD working solution

at 20x using an Olympus IX70 inverted microscope (Olympus Corpo-

(250 μL) was added to each well and incubated at 37°C for 30 min-

ration of the Americas, Center Valley, PA, USA).

utes. After incubation, confocal microscopy images (n = 3‐4/well,
totalling n = 16‐20/supplement, mainly from the middle of the well)
of cell fluorescence were obtained at 10x magnification for cell

2.7 | Statistical analysis

quantification using the Olympus FluoView 1000 confocal laser

Data was presented as mean ± SEM Statistical analysis was per-

scanning microscope (Olympus Corporation of the Americas, Center

formed using GraphPad Prism Software version 5 (GraphPad Soft-

Valley, PA, USA). Live cells were labelled with green fluorescence

ware, Inc.). The results for MNC hUCB viability and apoptotic

through the conversion of non‐fluorescent cell‐permanent calcein

activity were evaluated using a one‐way ANOVA with Tukey's Multi-

acetoxymethyl to intensely fluorescent calcein by ubiquitous intracel-

ple Comparison post‐hoc test. The results for cytokine and growth

lular esterase enzyme activity. Dead cells were identified using ethid-

factors in CBP were analyzed with a two‐tailed t test using same

ium homodimer‐1, which enters cells through damaged membranes

software. A value of P < 0.05 was considered significant.

and produces a red fluorescence upon binding to nucleic acids. Cell
counts of live (green) and dead (red) cells were determined using
NIH ImageJ software (version 1.46).

3 | RESULTS
3.1 | Cord blood plasma cytokine profile

2.6 | Apoptotic activity of MNC hUCB cultured
with autologous CBP

Samples of CBP and ABP/S were assayed to determine cytokine pro-

Cryopreserved MNC hUCB cells (n = 6 units) were quickly thawed

showed significantly (P < 0.01) lower concentrations of the pro‐

files using an ultrasensitive human cytokine 10‐plex panel. Results

at 37°C, washed with PBS, and centrifuged at 400 g for 5 minutes.

inflammatory cytokines IL‐2, IFN‐γ and TNF‐α in CBP compared to

Cell quantity and viability were determined using a haemocytometer.

ABP/S (Figure 1B,H,I). Additionally, levels of immunomodulatory IL‐5

Cells were then re‐suspended with phenol‐free RPMI‐1640 media

(Figure 1D) and multifunctional IL‐6 (Figure 1E) cytokines were also

and plated in a 96‐well culture plate at a density of 2 × 104 cells/

significantly (P < 0.01) lower in CBP vs. ABP/S. Significantly

well. Pre‐designated wells were supplemented with 10% of either

(P < 0.01) elevated concentrations of the chemokine IL‐8 were

autologous CBP, ABP/S, or FBS upon initial plating in duplicate. Cells

determined in CBP in comparison in ABP/S (Figure 1F). Interestingly,
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F I G U R E 1 Cord blood plasma cytokine profile. The cytokine profiles of CBP (n = 20) and ABP/S (n = 6) were assayed using an
ultrasensitive human cytokine panel in triplicate. Significantly lower concentrations of the pro‐inflammatory cytokines (B) IL‐2, (E) IL‐6, (H)
IFN‐γ and (I) TNF‐α were detected in CBP vs. ABP/S. Levels of immunomodulatory (D) IL‐5 cytokine and (J) GM‐CSF were significantly low in
CBP. A significant increase in (F) IL‐8 was also determined in CBP. There were no significant differences between CBP and ABP/S for (A) IL‐1β,
(C) IL‐4 and (G) IL‐10. **P < 0.01

levels of the pro‐inflammatory immune cell maturating factor, GM‐

higher in CBP vs. ABP/S. Levels of growth factors in CBP and ABP/S

CSF, were significantly (P < 0.01) lower in CBP than in ABP/S

are indicated in Table 1B.

(Figure 1J). Although the levels of IL‐1β, IL‐4 and IL‐10 were slightly
reduced in CBP compared to ABP/S, these reductions were not statistically significant (P > 0.05) (Figure 1A,C,G). While anti‐inflammatory IL‐4 and IL‐10 cytokine concentrations were not significantly

3.3 | Viability of MNC hUCB cultured with
autologous CBP

different between CBP and ABP/S, it is important to note that most

Cryopreserved MNC hUCB was incubated with RPMI‐1640 media

of the pro‐inflammatory cytokines within CBP were present at lower

supplemented with autologous CBP, ABP/S, or FBS for 5 days. After

concentrations than their anti‐inflammatory counterparts. Concentra-

5 days in vitro, the cells were stained using the LIVE/DEAD Viability/

tions of cytokines in CBP and ABP/S are provided in Table 1A.

Cytotoxicity assay to identify the viable (green fluorescence) and
non‐viable cytotoxic cell populations (red fluorescence). Numerous

3.2 | Cord blood plasma growth factor profile

viable MNC hUCB were observed in cultures with CBP (Figure 3Aa)
and FBS (Figure 3Ac) supplements. Fewer viable cells were seen

The levels of several common growth factors were measured in CBP

with ABP/S (Figure 3Ab) added into media. Live cell counts of MNC

and ABP/S using a human growth factor four‐plex assay. The con-

hUCB supplemented with autologous CBP were significantly

centrations of VEGF were significantly (P < 0.01) higher in CBP,

(83.83 ± 10.86 cell number, P < 0.05) higher vs. cultured cells sup-

more than two‐fold, vs. ABP/S (Figure 2A). The concentrations of

plemented with ABP/S (60.35 ± 5.50 cell number, Figure 3B). How-

G‐CSF, a bone marrow stem cell stimulating growth factor, were also

ever, numbers of viable cells cultured with CBP (83.83 ± 10.86 cell

significantly (P < 0.05) higher in CBP compared to ABP/S (Figure 2B).

number)

Also, the cell proliferating growth factors: epidermal growth factor

(Figure 3B). Importantly, media supplemented with CBP showed sig-

(EGF) and fibroblast growth factor basic (FGF‐basic) were signifi-

nificantly (P < 0.01) reduced numbers of dead MNC hUCB

cantly (P < 0.01) elevated in CBP (Figure 2C,D; respectively). Of

(22.50 ± 3.67 cell number) compared to FBS (79.33 ± 10.48 cell

note, the levels of EGF and FGF‐basic factors were about 2.5‐fold

number). Yet, MNC hUCB cultured with FBS demonstrated a

and

FBS

(87.33 ± 7.17

cell

number)

were

similar
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T A B L E 1 Cytokine and growth factor profiles in cord blood plasma and adult blood plasma/serum
A. Cytokine profile (pg/mL)
Cytokine

CBP

B. Growth factor profile (pg/mL)
ABP/S

Growth factor

IL‐1β

0.97 ± 0.14

1.24 ± 0.19

VEGF

CBP

IL‐2

0.93 ± 0.05**

2.29 ± 0.27

G‐CSF

59.89 ± 2.26*

46.22 ± 0.52

IL‐4

5.40 ± 0.28

6.05 ± 0.23

EGF

11.00 ± 0.41**

4.64 ± 0.13

IL‐5

1.17 ± 0.07**

1.93 ± 0.22

FGF Basic

6.07 ± 0.18**

2.35 ± 0.12

IL‐6

0.64 ± 0.07**

1.20 ± 0.17

IL‐8

13.02 ± 1.22**

2.98 ± 0.79

IL‐10

1.64 ± 0.08

1.91 ± 0.14

IFN‐γ

0.57 ± 0.08**

1.41 ± 0.21

TNF‐α

1.23 ± 0.07**

2.77 ± 0.25

GM‐CSF

1.91 ± 0.26**

4.46 ± 0.15

7.23 ± 0.28**

ABP/S
2.94 ± 0.11

Levels of cytokines and growth factors presented as mean ± SEM.
CBP: Cord Blood Plasma; ABP/S: Adult Blood Plasma/Serum; Interleukin (IL): 1β, 2, 4, 5, 6, 8, and 10; IFN‐γ: Interferon‐gamma; TNF‐α: Tumour necrosis
factor‐alpha; GM‐CSF: Granulocyte‐macrophage colony stimulating factor; VEGF: Vascular endothelial growth factor; G‐CSF: Granulocyte‐colony stimulating factor, EGF: Epithelial growth factor; FGF Basic: Fibroblast growth factor basic.
Significance of CBP vs. ABP/S denoted by: *P < 0.05; **P < 0.01.

F I G U R E 2 Cord blood plasma growth
factor profile. The levels of the growth
factors were analyzed in CBP (n = 20) and
ABP/S (n = 6) using a human growth factor
multiplex assay in triplicate. Significantly
higher concentrations of (A) VEGF, (B)
G‐CSF, (C) EGF and (D) FGF basic growth
factors were detected in CBP vs. ABP/S.
*P < 0.05, **P < 0.01

significant (P < 0.05) increase of dead cells vs. cultured cells supple-

using a colormetric TUNEL assay. The percentage of apoptotic cells

mented with ABP/S (38.15 ± 6.90 cell number, Figure 3B). Addition-

cultured with CBP was significantly lower (17.39 ± 1.70%) compared

ally, cells supplemented in media with CBP had a greater ratio of live

to cultures supplemented with ABP/S (34.72 ± 2.61%, P < 0.001) or

to dead cells (3.7:1) compared to cultures that received ABP/S (1.6:1)

FBS (26.62 ± 2.08%, P < 0.01) (Figure 4A). Interestingly, MNC hUCB

or FBS (1.1:1).

cultured in media containing FBS showed significantly (P < 0.05)
lower apoptotic activity vs. cultured cells with ABP/S. Phase contrast

3.4 | Apoptotic activity of MNC hUCB cultured
with autologous CBP

microscopic images of MNC hUCB in vitro demonstrated a few cells
with abnormal morphology displaying dislocated nuclei in cultures
supplemented with CBP (Figure 4Ba) compared to numerous mor-

Apoptotic activity of cultured MNC hUCB in media supplemented

phologically damaged cells cultured with ABP/S (Figure 4Bb) or FBS

with autologous CBP, ABP/S, or FBS was analyzed on day 5 in vitro

(Figure 4Bc), supporting apoptotic cell counts.
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F I G U R E 3 Viability of MNC hUCB in vitro. MNC hUCB (n = 4 units) was cultured for 5 d in media supplemented with either autologous
CBP, ABP/S, or FBS in duplicate. The cells were stained using the LIVE/DEAD Viability/Cytotoxicity assay to identify the viable (green
fluorescence) and non‐viable cytotoxic (red fluorescence) cell populations from images totalling n = 16‐20/supplemental condition. A, Confocal
microscopy images demonstrated numerous viable (green) MNC hUCB cultured with (Aa) CBP and (Ac) FBS supplements. Fewer viable cells
were detected in culture supplemented with (Ab) ABP/S. Scale bar in Aa‐Ac is 100 μm. (B) MNCs cultured with autologous CBP supplement
showed significantly greater cell survival vs. ABP/S. Also, media supplemented with CBP showed significantly reduced numbers of dead (red)
MNC hUCB compared to FBS. Cells supplemented in media with CBP had a greater live (green)/dead (red) cell ratio compared to cultures that
received ABP/S or FBS.*P < 0.05, **P < 0.01

4 | DISCUSSION
In the present study, various factors in CBP derived from hUCB and
the effect of CBP on mononuclear cells isolated from hUCB (MNC
hUCB) in vitro were evaluated in the context of establishing CBP as
a potential therapeutic agent. Cytokine and growth factor profiles
were examined within the same samples of CBP and human adult
blood plasma/sera (ABP/S). The effect of autologous CBP on MNC
hUCB in vitro was determined and compared to ABP/S and standard
FBS media supplements. The major study findings were that CBP
demonstrated: (a) significantly “low” concentrations of the pro‐
inflammatory cytokines IL‐2, IL‐6, IFN‐γ, and TNF‐α; (b) significantly
“low” concentrations of immunomodulatory IL‐5 cytokine and
GM‐CSF; (c) significantly “elevated” level of the chemokine IL‐8; (d)
significantly high concentrations of VEGF, G‐CSF, EGF and
FGF‐basic growth factors; (e) significantly “increased” viability of
MNC hUCB in vitro with autologous CBP media supplement; and (f)
significantly “decreased” apoptotic MNC hUCB in vitro with autoloF I G U R E 4 Apoptotic activity of MNC hUCB in vitro. MNC hUCB
(n = 6 units) was cultured for 5 d in media supplemented with either
autologous CBP, ABP/S, or FBS in duplicate. Apoptosis was detected
by TUNEL assay. A, MNCs cultured in autologous CBP showed a
significantly lower percentage of apoptotic absorbance vs. cultures
supplemented with ABP/S or FBS. Cells incubated with FBS also
exhibited significantly lower absorbance of apoptotic activity
compared to ABP/S. *P < 0.05, **P < 0.01, ***P < 0.001. B, Phase
contrast images of MNC hUCB in vitro demonstrated a few cells
with abnormal morphology displaying dislocated nuclei in cultures
supplemented with (Ba) CBP compared to numerous morphologically
damaged cells cultured with (Bb) ABP/S or (Bc) FBS, supporting
apoptotic cell counts. Arrowheads indicate healthy cells with normal
morphology. Arrows indicate cells with abnormal morphology. Scale
bar in Ba‐Bc is 50 μm

gous CBP media supplement. To our knowledge, we are the first to
demonstrate the unique CBP composition of cytokines and growth
factors within the same samples, providing evidence of the unique
protein content in CBP. Also, our novel finding is that autologous
CBP promoted MNC hUCB viability and reduced apoptotic cell
death in vitro, supporting the notion that CBP has potential as a sole
therapeutic or cell‐additive agent in developing clinically relevant
CBP‐based therapies for various neurodegenerative diseases.
In development of alternative approaches in treatment for age‐
related diseases, proteins from “young” blood have been intensely
investigated. Studies of parabiosis, with shared blood circulatory systems between old (16‐20 months of age) and young (2‐3 months of
age) mice, have shown significantly improved cognition and physical
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function in both aged wild‐type mice14 and a mouse model of Alz-

a favourable microenvironment for cellular content in hUCB. It has

heimer's disease (AD).15 Middeldorp et al15 demonstrated that para-

been shown that transplantation of MNC derived from hUCB even

biosis of young wild‐type mice with AD mice for 5 weeks effectively

from unrelated donors into patients with haematologic malignancies

improved learning and memory while also reducing inflammation in

causes a low incidence of graft‐versus‐host disease compared to

AD mice. Additionally, the authors noted increased synaptic activity

bone marrow or peripheral blood cell administration.22,23

in the hippocampus of AD mice. Based on these study results, clini-

Our study results also demonstrated similar amounts of anti‐

cal trial (NCT02256306) investigated the safety of 4‐weekly infu-

inflammatory IL‐4 and IL‐10 cytokines in CBP and ABP/S, However,

sions of young blood plasma from donors aged between 18 and

it is important to note that these anti‐inflammatory cytokines were

30 years of age into patients with AD. Although no serious adverse

present at a greater concentration than the pro‐inflammatory con-

reactions occurred, the study found no significant effect on patient

stituents of CBP, suggesting a favourable cytokine composition

cognition but did show significant improvements in daily living skills.

towards developing CBP as potential therapeutic agent. Since IL‐10

Although results of using young blood are promising, it is still unclear

is an important cytokine for downregulation of Th1 inflammatory

which constituents of “young” blood are providing beneficial effects.

cytokines and MHC class II antigens, a decrease of this cytokine is

Potentially, paracrine actions are involved in positive outcomes for

mainly associated with altered cell‐mediated immunosuppression and

treatment of an age‐related disease such as AD. Also, hormonal sta-

induction of complications during pregnancy.24 In contrast, increased

tus of donors should be investigated due to the wide age range (18‐

cord blood IL‐10 was determined in preterm infants compared to

30 years) of donors. Alternatively, plasma derived from hUCB could

full‐term newborns.25,26 In our study, hUCB units were used from

be a more beneficial therapeutic due to its unique and uniform

healthy infants delivered naturally, so IL‐10 levels determined in CBP

molecular composition.

vs. ABP/S likely reflect steady immune/inflammatory humoral status

It has been shown that in addition to a high concentration of
16

in hUCB.

growth factors (reviewed ), human CBP also contains a great

Amongst our additional important study findings were significant

amount of soluble proliferative and immunomodulatory factors such

elevations of VEGF, G‐CSF, EGF and FGF‐basic growth factors in

as (TGF)‐β, G‐CSF, GM‐CSF, monocyte chemoattractant protein

CBP vs. ABP/S. Both EGF and FGF‐basic promote stem cell renewal

(MCP)‐1, IL‐6, and IL‐8.17 Also, IL‐16 cytokine, a modulator of T cell

and inhibit cell senescence27 and elevated levels of EGF largely cor-

18

and potentially presents a

relate to gestational age and birth weight of the developing foe-

physiological mechanism for foetal‐maternal tolerance. Due to CBP's

tus.28,29 Thus, the increased levels of EGF and FGF‐basic in CBP

activation, has been detected in CBP

1-4

showed benefi-

determined in our study may indicate normal foetal development.

cial effect of CBP in replacement of standard FBS for various cell

Also, increased G‐CSF, a bone marrow stem cell mobilizing factor, in

expansions in vitro, which may be essential to achieve appropriate

CBP potentially reflects intensive production of bone marrow

cell numbers for clinical use.

derived stem cells in the foetus. The combination of this growth fac-

specific molecular composition, numerous studies

In our study, cytokine and growth factor levels were analyzed in

tor with MNC hUCB for the treatment of myeloid malignancies in

the same CBP samples for a better understanding of CBP molecular

human adults after radiation promoted cell engraftment in bone mar-

composition prior to proposing CBP as a therapeutic agent. We

row replacement therapies.30,31 Also, co‐administration of G‐CSF

showed low concentrations of pro‐inflammatory IL‐2, IL‐6, IFN‐γ and

with MNC hUCB into an animal model of traumatic brain injury

TNF‐α cytokines in CBP, presumably secreted by various cells in

results demonstrated reduction of neuroinflammation and promotion

hUCB, which, likely signify the immune immaturity of these cell pop-

of stem cells into the injured side of the brain.32

ulations. Additionally, our study findings demonstrated a significantly

Of note, significantly elevated levels of the chemokine IL‐8 and

low concentration of immunomodulatory cytokine IL‐5 in CBP vs.

VEGF were determined in CBP vs. ABP/S in our study. While IL‐8 is

ABP/S, supporting previous study results.19 This cytokine, mainly

primarily known as a pro‐inflammatory mediator, it also recognized

produced by Th2 helper lymphocytes and mast cells, promotes

as a promoter of angiogenic activity as demonstrated by endothelial

growth/differentiation of B cells and granulocytes upon immunologi-

cell survival, proliferation and migration in vitro.33,34 Interestingly,

cal and/or antigenic priming in development of the adaptive immune

the concentration of the angiogenic VEGF growth factor was also

response. However, increased concentrations of IL‐5, IL‐2 and tran-

significantly higher in CBP vs. ABP/S. It is possible that the elevated

scription factor GATA‐4 determined in CBP may result in abnormal

level of VEGF is a result of the high concentration of IL‐8, which

patterns of foetal immune system development and induce risk of

promotes increased expression of VEGF by endothelial cells.35,36 A

20

Also, it has been shown that antioxidant capacity,

recently published study37 demonstrated that microRNA‐containing

evaluated by carbonyl levels in CBP, was significantly higher in

exosomes derived from maternal and umbilical cord serum dramati-

patients delivering neonates by caesarean vs. vaginal route, suggest-

cally promote human umbilical vein endothelial cell proliferation,

ing that the delivery method impacts oxidative stress.21 In our study,

migration, and tube formation in vitro, highlighting the important role

the low concentration of GM‐CSF found in CBP together with the

of exosomes in the regulation of angiogenesis during gestation.

low concentrations of pro‐inflammatory cytokines provide further

Exclusively, VEGF has been studied for potential therapeutic efficacy

evidence of anti‐inflammatory hUCB content. Thus, low levels of

in animal models of ALS38,39 and its use in clinical settings has been

pro‐inflammatory and immunomodulatory cytokines in CBP provide

discussed (reviewed40). Nevertheless, CBP containing high levels of

allergic disease.
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IL‐8 and VEGF might be a beneficial treatment for repair of the damaged blood–brain barrier and/or blood–spinal cord barrier in patients
with ALS,41-44 AD,45 Parkinson's disease46 and multiple sclerosis.47
Finally, our in vitro studies showed significantly increased viability of MNC hUCB when autologous CBP was added to culture
media. Also, apoptotic activity of MNC hUCB in vitro, determined by
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TUNEL, was also decreased after autologous CBP exposure compared to cultures supplemented with ABP/S or FBS. Supporting this
novel finding, our previous study has demonstrated reduced activities of other pro‐apoptotic factors, such as caspase 3/7, from ALS
patient‐derived MNC's cultured in media supplemented with CBP.11
In this context, numerous studies have shown neuroprotective
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effects of MNC hUCB administered into animal models of ALS,48-51
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brain injury.58,59 However, insignificant numbers of MNC hUCB
were detected in the CNS of these animal models after intravenous
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cell administration. This scarcity is likely due to a low rate of cell survival, since cell preparation and injection involve dilution with a basic
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